<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>MapLight Therapeutics — Prospect Detail</title>
  <link rel="stylesheet" href="styles.css">
</head>
<body>
<header class="site-header"><h1>Prospect Detail</h1></header>
<div class="container">
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
  <div class="detail-header">
    <span class="badge health" style="font-size:.8rem;">Digital Health</span>
    <h1>62. MapLight Therapeutics</h1>
    <p class="meta">Brain Disorder Therapeutics</p>
  </div>
  <div class="section"><h3>1. Startup Name</h3><p><strong>MapLight Therapeutics</strong></p></div>
  <div class="section"><h3>2. Founder Contact</h3><p><strong>Chris Kroeger</strong></p><p>Harvard Business School '03</p><p>Serial biotech entrepreneur with multiple successful exits</p></div>
  <div class="section"><h3>3. Product Overview</h3><p>MapLight Therapeutics develops therapeutics for brain disorders and neurological diseases. The company focuses on novel mechanisms to treat conditions like schizophrenia and other CNS disorders where current treatments have significant limitations.</p></div>
  <div class="section"><h3>4. Funding Stage</h3><p><strong>Series C</strong> — Raised $225M to advance clinical development programs.</p></div>
  <div class="section"><h3>5. How I Found the Company</h3><p>Discovered through HBS alumni funding news and neuroscience therapeutics coverage.</p></div>
  <div class="strengths-weaknesses">
    <div class="section"><h3>Strengths</h3><ul><li><strong>Huge unmet need:</strong> CNS disorders affect hundreds of millions with limited treatment options.</li><li><strong>Experienced team:</strong> Serial entrepreneurs with pharma development expertise.</li></ul></div>
    <div class="section"><h3>Weaknesses</h3><ul><li><strong>CNS drug development risk:</strong> Brain disorder drugs have historically high failure rates.</li><li><strong>Long timelines:</strong> CNS clinical trials often take 10+ years to complete.</li></ul></div>
  </div>
  <div class="section"><h3>7. Five Questions for the Team</h3><ol class="questions-list"><li>What stage are your lead candidates in clinical development?</li><li>What novel mechanisms differentiate your approach from existing CNS drugs?</li><li>How do you recruit patients for CNS clinical trials?</li><li>What is your partnership strategy with large pharma companies?</li><li>What are the key milestones for the next 18-24 months?</li></ol></div>
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
</div>
</body>
</html>
